Oridecin (Dexamethasone, Tobramycin)

Dexamethasone and Tobramycin, the active ingredients in Oridecin, are a corticosteroid and an aminoglycoside antibiotic presented as an ophthalmic solution for topical eye use. The combination is employed to reduce ocular inflammation while treating bacterial eye infections.

GNH USA supplies Oridecin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oridecin is used in ophthalmology to manage inflammatory and bacterial conditions of the eye.

- Bacterial conjunctivitis: reduces bacterial load and resolves infection. - Post‑operative ocular inflammation: controls swelling and pain after eye surgery. - Sterile keratitis: treats inflammation associated with bacterial keratitis. - Allergic eye disease with secondary infection: alleviates inflammation while addressing bacterial components. - Uveitis with suspected bacterial involvement: suppresses intra‑ocular inflammation and combats infection.

Adverse reactions may occur with ocular administration of Oridecin.

Common Side Effects: - Eye irritation or burning sensation. - Transient blurred vision. - Mild ocular redness. - Increased intra‑ocular pressure. - Temporary headache. - Localized allergic rash.

Serious or Rare Side Effects: - Secondary ocular infection. - Severe allergic reaction (anaphylaxis). - Cataract formation with prolonged use. - Glaucoma development. - Corneal ulceration. - Vision loss.

Use Oridecin only under professional supervision and observe the following precautions.

- Intra‑ocular pressure monitoring: check pressure regularly during therapy. - Infection assessment: avoid if viral or fungal eye infection is suspected. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Diabetes caution: monitor blood glucose as steroids may affect control. - Pregnancy and lactation: consult a physician before use. - Store at room temperature: keep in the original container, protect from moisture and light.

Oridecin may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Concurrent corticosteroid eye drops: risk of additive steroid effects. - Systemic immunosuppressants: may increase infection risk. - Anticholinergic eye drops: can elevate intra‑ocular pressure. - CYP3A4 inducers (e.g., rifampicin): may reduce dexamethasone exposure. - Systemic aminoglycosides: potential additive ototoxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may affect healing. - Antihistamine eye drops: possible reduced efficacy. - Systemic NSAIDs: monitor for gastrointestinal irritation. - Antifungal eye preparations: assess for overlapping toxicity. - Diuretics: watch for changes in intra‑ocular pressure.